Cutaneous Mycobacterium Ulcerans Infection

Cutaneous Mycobacterium ulcerans infection, also called Buruli ulcer, is a skin disease caused by a slow-growing bacterium named Mycobacterium ulcerans. The germ makes a toxin called mycolactone. This toxin quietly damages the skin, the fatty tissue under the skin, and sometimes bone. At first, a painless lump or swelling appears. Over days to weeks, this area breaks down and turns into a deep ulcer with undermined edges. Many people feel little or no pain and may not have fever. Without care, the ulcer can enlarge and cause scars, contractures, or disability. With correct antibiotics and good wound care, most people recover. Nature+3World Health Organization+3World Health Organization+3

Cutaneous Mycobacterium ulcerans infection, also called Buruli ulcer, is a slowly growing skin infection caused by a mycobacterium that makes a toxin named mycolactone. This toxin damages skin and soft tissue, so early lumps or plaques can slowly break down into deep, painless ulcers. The disease is most common near wetlands and slow-moving water in parts of West and Central Africa, Australia, and a few other regions. It usually does not spread from person to person. Quick diagnosis and 8 weeks of oral antibiotics plus good wound care can prevent disability and shorten healing. World Health Organization+2World Health Organization+2

Scientists still do not fully know how people get infected. Evidence links the germ to aquatic environments, biofilms, and sometimes biting insects in certain settings; in Australia, local data suggest a cycle including possums and mosquitoes. Because the exact route can differ by region and is not proven everywhere, health advice focuses on general bite prevention, protecting skin, and fast cleaning of cuts. PMC+3PMC+3PLOS+3

Today, treatment has shifted from routine surgery to antibiotics as first-line therapy. The World Health Organization (WHO) recommends rifampicin (rifampin) plus clarithromycin for 8 weeks, usually without injections. Surgery (such as debridement or grafting) is reserved for selected cases—e.g., large dead tissue, unstable wound edges, or to correct deformities after infection is controlled. World Health Organization+2WHO | Regional Office for Africa+2

---

Other names

• Buruli ulcer (global name).

• Bairnsdale ulcer (Victoria, Australia).

• Daintree ulcer (Queensland, Australia).

• Sometimes called a “flesh-eating” ulcer in news stories (not a medical term).
  These names all refer to the same disease caused by M. ulcerans. World Health Organization+2Health Victoria+2

---

Types

1. Nodule – a firm, painless lump in the skin; may look like an insect-bite at first.

2. Plaque – a larger, raised, firm area.

3. Oedematous (swollen) form – diffuse, soft swelling; the skin may be warm and tender, and the swelling can be mistaken for cellulitis.

4. Ulcerative form – the most common; a deep ulcer with undermined edges and a clean base.

5. Multiple lesions – more than one area involved.

6. Lesions with bone involvement (osteomyelitis) – when infection tracks to bone, causing pain, swelling, and possible deformity.

7. Paradoxical reaction during treatment – temporary worsening or new lesions after starting antibiotics because the immune system “wakes up.”
   These are recognized clinical patterns used in diagnosis and care. PMC+1

---

Causes

Important note: There is one true cause—infection by Mycobacterium ulcerans. The list below explains exposures and risk factors that are linked to getting the germ or developing disease. Researchers are still studying the exact transmission route. World Health Organization+1

1. Infection by Mycobacterium ulcerans – the essential cause; the bacterium plus its toxin mycolactone drive the tissue damage. Nature

2. Living near or visiting wetlands, slow rivers, swamps, or ponds – the germ is environmental and clusters around such areas. World Health Organization

3. Mosquito exposure in some regions (e.g., Australia) – ecological and molecular studies suggest a link. Health Victoria

4. Wildlife reservoirs (e.g., possums in parts of Australia) – animal–environment cycles may maintain the bacterium. Wildlife Health Australia

5. Skin trauma or minor injuries – scratches, bites, or cuts may allow entry. PMC

6. Poor wound hygiene after minor skin breaks – delayed cleaning/dressing may increase risk in endemic areas. PMC

7. No protective clothing outdoors in endemic zones (short sleeves/legs increase exposure). Health Victoria

8. Not using insect repellent where mosquitoes may play a role. Health Victoria

9. Lack of safe water/sanitation nearby – broad environmental exposure patterns correlate with disease clusters. Iris

10. Delayed care for early lesions – allows toxin to spread and ulcers to form. World Health Organization

11. Younger age in endemic African settings – some surveys find more cases in children, likely due to exposure behaviors. Iris

12. Older age in Australian settings – local epidemiology shows many cases in older adults. Health Victoria

13. Seasonal patterns – cases sometimes cluster after wet seasons. Iris

14. Living or traveling in known endemic districts (e.g., parts of West/Central Africa; coastal Victoria/Queensland in Australia). World Health Organization+1

15. No prior awareness/education about early painless signs—people wait, lesions enlarge. World Health Organization

16. Potential exposure during farming/fishing where skin is frequently wet or scratched. Iris

17. Household or community proximity to recent cases – suggests shared environment (not person-to-person spread). Iris

18. Handling contaminated items/soil/water in endemic areas – environmental contact remains the leading hypothesis. Iris

19. Impaired local immunity at the skin (e.g., chronic steroid use on skin) may raise risk of progression if exposed. PMC

20. Unknown factors still under study – transmission is not fully defined; research continues. World Health Organization

---

Symptoms and signs

1. Painless lump or swelling that slowly grows. Many people feel no pain at first. World Health Organization

2. Painless plaque or thickened skin area that may feel firm to touch. PMC

3. Deep ulcer with undermined edges—the skin at the rim overhangs; the base looks clean. World Health Organization

4. Swollen limb or face (oedematous form), sometimes warm and tender. PMC

5. Minimal or no fever—people often feel otherwise well. World Health Organization

6. Little pain even with big ulcers, because the toxin numbs tissue. Pain can rise if secondarily infected. Nature

7. Draining wound fluid with slow healing. PMC

8. Pigment changes or shiny scars after healing. PMC

9. Stiffness or reduced movement if the ulcer crosses a joint; later contractures may develop. World Health Organization

10. Swollen lymph nodes near the lesion in some patients. PMC

11. Secondary bacterial infection—new pain, redness, or pus. PMC

12. Bone pain or tenderness if the infection reaches bone (osteomyelitis). PMC

13. New nodules along lymph channels (satellite lesions). PMC

14. Temporary worsening after starting antibiotics (paradoxical reaction) with more redness or new small lesions. PMC

15. Functional limits and disability if care is delayed—difficulty walking, working, or using the limb. World Health Organization

---

Diagnostic tests

Diagnosis uses clinical assessment plus lab confirmation whenever possible. The most useful tests are PCR for M. ulcerans (usually IS2404 target), histopathology, and microscopy/culture. Imaging and other studies help define complications, not the germ itself. CDC+3World Health Organization+3CDC+3

A) Physical examination (at the bedside)

1. Full skin inspection
   The clinician looks for a painless nodule, plaque, or undermined ulcer in a person from (or who visited) an endemic area. The “painless, undermined ulcer” pattern is a classic clue and should prompt testing and early antibiotics. World Health Organization

2. Size, depth, and edge assessment
   Measuring the lesion and feeling its base help stage severity and guide wound care and surgery planning. Undermined edges and a clean base point toward Buruli ulcer. PMC

3. Check for oedema and warmth
   A soft, diffuse swelling may be the oedematous form. It can mimic cellulitis; careful exam plus PCR can separate them. PMC

4. Regional lymph node exam
   Enlarged nodes can occur near lesions. The finding supports, but does not prove, the diagnosis. PMC

5. Joint range-of-motion testing
   Ulcers crossing joints can limit movement. Early splints and physiotherapy prevent contractures. Exam findings also help track recovery. World Health Organization

B) Manual/bedside procedures

6. Sterile swab of undermined ulcer edge
   A trained worker collects material from the undermined edge for PCR and microscopy. Swabs are less invasive than biopsies and are widely used for lab confirmation. PMC

7. Fine-needle aspiration (FNA)
   For nodules or plaques without open ulcers, FNA collects material for PCR or smear. It is quick and causes little scarring. PMC

8. Punch or excisional skin biopsy
   If needed, a small core of tissue is taken for PCR, histopathology, and culture. Biopsy is especially useful when the diagnosis is uncertain. PMC

9. Wound probing and mapping
   Gentle probing defines undermining and dead space to plan dressings and, if needed, surgery. This is not a lab test but helps safe management. PMC

10. Photography and serial measurements
    Standardized photos and measurements track healing or paradoxical reactions during therapy. PMC

C) Laboratory and pathological tests

11. PCR for M. ulcerans (IS2404 target) – the main confirmatory test
    PCR detects M. ulcerans DNA with high sensitivity and specificity, especially on swabs or tissue. Targeting the IS2404 sequence is standard. Results support early treatment. CDC+1

12. Microscopy (acid-fast bacilli smear)
    Ziehl–Neelsen staining may show clumps of acid-fast bacilli in tissue. Smear is fast but less sensitive than PCR. A positive smear supports the diagnosis. PMC

13. Culture for M. ulcerans
    Culture confirms living bacteria but is slow and insensitive; the organism grows at lower temperatures (≈30–33 °C) and may take weeks. Negative culture does not exclude disease. PMC

14. Histopathology of skin/tissue
    Typical features include necrosis of subcutaneous fat, minimal inflammation, and clumps of acid-fast bacilli. Histology helps when PCR is unavailable and to exclude mimics. CDC+1

15. Loop-mediated isothermal amplification (LAMP)
    A rapid DNA test that can be done closer to the point of care. It shows promise where PCR labs are limited. PMC

16. Bacterial culture/susceptibility for secondary infection
    If the ulcer looks infected (new pain, pus, odor), cultures for common bacteria help guide additional antibiotics for superinfection (not for M. ulcerans itself). PMC

17. Basic blood tests (CBC, CRP)
    These are often normal in uncomplicated Buruli ulcer but help assess inflammation, anemia from chronic wounds, or other conditions when planning surgery or prolonged care. PMC

D) Electrodiagnostic tests

18. Not routinely used
    There are no standard electrodiagnostic tests (like nerve conduction studies or EMG) for diagnosing Buruli ulcer. They may be considered only if there is suspected nerve damage from scarring or contracture, but this is uncommon and not part of routine work-up. PMC

E) Imaging tests (for extent, not for confirming the germ)

19. Ultrasound of soft tissue
    Helps detect fluid collections, abscesses, or sinus tracts, and guides aspiration. Useful in oedematous disease and in surgical planning. PMC

20. X-ray or MRI when bone is suspected
    If there is bone pain or non-healing deep ulcers near bone, imaging checks for osteomyelitis and guides orthopedic input. MRI shows marrow and soft tissue spread. PMC

Non-pharmacological treatments (therapies & others)

1) Early wound cleansing and moist wound care (daily):
Gently wash the lesion with clean water and mild soap, remove loose debris, and keep the wound moist, not wet, using modern dressings (e.g., hydrofiber, foam) to support granulation and re-epithelialization. Moist wound healing shortens time to closure and reduces pain compared with dry dressings. PMC+1

Purpose: reduce bacterial burden, toxin-damaged slough, and protect new tissue so antibiotics can work. PMC
Mechanism: gentle irrigation lowers surface bioburden; moist dressings maintain optimal temperature and humidity, supporting keratinocyte migration and collagen deposition. Taylor & Francis Online

2) Atraumatic debridement (as needed):
Use conservative sharp or autolytic debridement (via moisture-retentive dressings) to remove necrotic tissue that feeds bacteria and blocks healing. Avoid aggressive debridement until antibiotics blunt active inflammation. Taylor & Francis Online

Purpose: convert a chronic, toxin-damaged wound into a cleaner bed ready to heal. Taylor & Francis Online
Mechanism: removal of devitalized tissue decreases proteases and promotes healthy granulation. Taylor & Francis Online

3) Pain control & comfort measures:
Even “painless” BU ulcers hurt during care; schedule dressing changes after analgesics, elevate the limb, and pad dressings to reduce shear and pressure. Taylor & Francis Online

Purpose: better tolerance of daily care and improved mobility. Taylor & Francis Online
Mechanism: analgesia reduces central sensitization, while limb elevation reduces edema that slows healing. Taylor & Francis Online

4) Edema management & limb elevation:
Elevate affected limbs and, when appropriate, use light compression once acute pain and infection are controlled to limit swelling around large ulcers. Taylor & Francis Online

Purpose: reduce tissue pressure and improve microcirculation. Taylor & Francis Online
Mechanism: lower interstitial fluid -> better oxygen and nutrient delivery for repair. Taylor & Francis Online

5) Physiotherapy and range-of-motion exercises:
Start gentle movement early, especially near joints (ankle, elbow), to prevent contractures and stiffness. Continue formal physiotherapy for large, slow-healing ulcers. World Health Organization

Purpose: prevent disability and maintain function during long healing. World Health Organization
Mechanism: movement aligns collagen, prevents capsular tightness, and improves lymphatic flow. World Health Organization

6) Splinting or positioning (short-term):
Use removable splints to keep joints in a functional position if the ulcer crosses a flexion crease while continuing brief daily ROM. Taylor & Francis Online

Purpose: prevent contractures without sacrificing mobility. Taylor & Francis Online
Mechanism: controlled immobilization limits shortening of soft tissues during healing. Taylor & Francis Online

7) Scar management after closure:
Once epithelialized, use silicone gel/sheets and gentle massage to flatten hypertrophic scars and improve pliability. Taylor & Francis Online

Purpose: reduce tightening that can limit motion. Taylor & Francis Online
Mechanism: silicone improves hydration and down-regulates fibroblast activity. Taylor & Francis Online

8) Nutritional optimization:
Aim for adequate calories (≈30–35 kcal/kg/day) and protein (≈1.25–1.5 g/kg/day) if at risk of malnutrition; add micronutrients when diet is insufficient. E-ACNM

Purpose: fuel collagen synthesis and immune responses for faster repair. E-ACNM
Mechanism: protein provides amino acids for matrix; vitamins C/A and zinc support collagen cross-linking and epithelialization. E-ACNM

9) Vitamin C–rich intake (diet ± supplement as needed):
For patients with low intake, add citrus/guava/vegetables or short-term supplements to support collagen formation. PMC

Purpose: support tensile strength of new tissue. PMC
Mechanism: vitamin C is a cofactor for prolyl/lysyl hydroxylases in collagen. Cambridge Media Journals

10) Zinc adequacy (diet ± short course):
If diet is poor or deficiency suspected (hair loss, brittle nails, poor appetite), use foods like meat/legumes or brief supervised supplements. drjeffreyjanis.com

Purpose: improve epithelialization and host defense when deficient. drjeffreyjanis.com
Mechanism: zinc supports DNA synthesis, keratinocyte migration, and innate immunity. drjeffreyjanis.com

11) Gentle offloading & pressure redistribution:
Use cushions, crutches, or modified footwear to avoid continuous pressure on ulcers, especially on legs/feet. Taylor & Francis Online

Purpose: prevent mechanical delay to closure. Taylor & Francis Online
Mechanism: reduced shear/pressure lowers ischemia and micro-tears in fragile tissue. Taylor & Francis Online

12) Antiseptic care for surrounding skin (not in wound bed):
Apply dilute chlorhexidine or povidone-iodine to intact periwound skin when there is heavy exudate to reduce maceration and contamination. Avoid cytotoxic agents inside clean granulating beds. Taylor & Francis Online

Purpose: protect edges and reduce secondary infection. Taylor & Francis Online
Mechanism: lowers surface microbes and moisture damage around the ulcer. Taylor & Francis Online

13) Psychosocial support and stigma reduction:
Offer counseling and community education; stigma can reduce care-seeking and adherence. World Health Organization

Purpose: improve early presentation and adherence to 8-week therapy. World Health Organization
Mechanism: education reduces fear, enabling timely, continuous care. World Health Organization

14) Sun protection of scars and healing tissue:
Cover new skin and use shade to reduce hyperpigmentation and scar thickening. Taylor & Francis Online

Purpose: better cosmetic and functional results. Taylor & Francis Online
Mechanism: UV avoidance reduces inflammation and abnormal collagen. Taylor & Francis Online

15) Lymphoedema care when present:
Teach basic skin care, elevation, exercise, and (when feasible) light compression for swelling associated with extensive lesions. World Health Organization

Purpose: reduce infection risk and improve mobility. World Health Organization
Mechanism: improved lymph flow decreases stagnant inflammatory mediators. World Health Organization

16) Community-based follow-up:
Use regular clinic or outreach visits to ensure adherence, manage dressings, and detect contractures early. World Health Organization

Purpose: keep care continuous during long healing. World Health Organization
Mechanism: frequent review enables timely changes in dressings and therapy. World Health Organization

17) Education on wound hygiene at home:
Demonstrate handwashing, clean water use, and safe dressing disposal to families. PMC

Purpose: lower reinoculation and secondary infection. PMC
Mechanism: fewer contaminants around the wound supports antibiotic success. PMC

18) Probiotic-adjunct (research/optional):
Some studies suggest oral or topical probiotics may aid wound-healing dynamics, but the overall evidence is mixed and not BU-specific; use only as adjuncts, not instead of antibiotics. PMC+1

Purpose: potential support for local immunity and re-epithelialization. Wiley Online Library
Mechanism: certain strains may modulate inflammation and compete with pathogens; evidence remains evolving. MDPI

19) Smoking cessation & alcohol moderation:
Where applicable, stop smoking and limit alcohol to improve microvascular flow and immune function. ScienceDirect

Purpose: reduce delays in collagen formation and infection risk. ScienceDirect
Mechanism: nicotine and alcohol impair leukocyte function and fibroblast activity. ScienceDirect

20) Rehabilitation after healing:
Continue strengthening, stretching, and vocational rehab to restore independence, especially after large thigh/leg lesions. World Health Organization

Purpose: minimize long-term disability and improve quality of life. World Health Organization
Mechanism: graded exercise rebuilds muscle and joint range after prolonged immobilization. World Health Organization

---

Drug treatments

Core principle: WHO’s preferred regimen is rifampicin + clarithromycin for 8 weeks. Other agents appear in alternative or study regimens; dosing below references FDA labels for general safety and class info, not BU-specific approvals. Always follow a local infectious-disease specialist’s plan. World Health Organization+1

1) Rifampicin (rifampin):
Class: rifamycin antibacterial. Typical adult dose in BU programs: 10 mg/kg once daily (max 600 mg) for 8 weeks, combined with clarithromycin. Timing: morning on empty stomach improves absorption. Purpose: backbone drug active against slow-growing mycobacteria. Mechanism: inhibits bacterial RNA polymerase; synergizes with macrolides. Side effects: orange body fluids, drug–drug interactions (strong CYP inducer), hepatotoxicity; check interactions (e.g., warfarin, OCPs, azoles). Label source: FDA label provides interaction and hepatotoxicity details used to screen risks. WHO | Regional Office for Africa+1

2) Clarithromycin:
Class: macrolide. Dose in BU programs: 7.5 mg/kg twice daily (or ER 15 mg/kg once daily) for 8 weeks with rifampicin. Timing: with or without food (ER with food). Purpose: partner to rifampicin in all-oral regimen. Mechanism: binds 50S ribosome, inhibiting protein synthesis; activity shown against M. ulcerans. Side effects: dysgeusia, GI upset, QT prolongation risk, CYP3A interactions (statins, some CCBs). Label source: FDA BIAXIN label informs interaction/QT cautions. WHO | Regional Office for Africa+1

3) Moxifloxacin (alternative component in selected cases):
Class: fluoroquinolone. Dose (general label reference): 400 mg once daily; BU data are limited and not first-line. Purpose: sometimes studied as alternative when macrolides cannot be used. Mechanism: DNA gyrase/topoisomerase IV inhibition. Side effects: tendinopathy, QT prolongation, dysglycemia; weigh risks. Label source: FDA AVELOX label. FDA Access Data+1

4) Levofloxacin (backup where expert-guided):
Class: fluoroquinolone. Dose (label): 500–750 mg daily depending on indication; BU use is off-label and specialist-directed only. Purpose: potential alternative partner when intolerance to macrolides occurs. Mechanism: inhibits DNA gyrase/topo IV. Side effects: boxed warnings—tendinopathy, neuropathy, CNS effects, QT risk. Label source: FDA LEVAQUIN label. FDA Access Data

5) Amikacin (injectable, legacy/selected severe cases):
Class: aminoglycoside. Dose: weight-based IV/IM with drug-level monitoring; streptomycin was used historically but is less favored now due to toxicity and all-oral options. Purpose: partner to rifampicin in severe or refractory disease under specialist care. Mechanism: 30S ribosome inhibition, bactericidal. Side effects: nephro/ototoxicity—use only with monitoring. Label source: FDA amikacin labeling (general safety). CDC

6) Doxycycline (rare/adjunct):
Class: tetracycline. Dose (label): usually 100 mg twice daily for susceptible infections; BU evidence limited. Purpose: not standard; may be used if other agents contraindicated. Mechanism: 30S inhibition. Side effects: photosensitivity, esophagitis; avoid in pregnancy/young children per local guidance. Label source: FDA doxycycline labels. CDC

7) Azithromycin (substitute macrolide if clarithromycin not tolerated):
Class: macrolide. Dose (label reference): 500 mg daily typical for many infections; BU data are modest. Purpose: macrolide alternative with fewer interactions. Mechanism: 50S inhibition. Side effects: QT risk, GI upset. Label source: FDA azithromycin label. CDC

8) Clofazimine (selected programs; access controlled):
Class: riminophenazine. Dose (programmatic): specialist-directed; may be added in complex or recurrent disease. Purpose: potential companion for rifampicin in difficult cases. Mechanism: interferes with mycobacterial respiration; anti-inflammatory. Side effects: skin discoloration, GI effects. Source: reviews of BU therapy discussing alternatives. PMC

9) Trimethoprim–sulfamethoxazole (TMP-SMX; occasional adjunct):
Class: folate pathway inhibitor combo. Dose (label): e.g., DS 160/800 mg twice daily for susceptible infections; BU role uncertain. Purpose: alternative when other options unsuitable. Mechanism: sequential blockade of folate synthesis. Side effects: hypersensitivity, cytopenias, hyperkalemia. Label source: FDA TMP-SMX labels. CDC

10) Linezolid (last-line, specialist-only):
Class: oxazolidinone. Dose (label): 600 mg every 12 h; BU evidence minimal. Purpose: salvage when intolerance/resistance suspected. Mechanism: 50S (23S) inhibition at initiation complex. Side effects: cytopenias, neuropathy; monitor if >2 weeks. Label source: FDA linezolid label. CDC

11) Rifapentine (investigational interest):
Class: rifamycin with long half-life. Dose: label regimens for TB differ; BU data are not established. Purpose: potential future simplification; not standard of care. Mechanism/risks: similar to rifampin with interactions. Label source: FDA rifapentine label. CDC

12) Delamanid (research contexts only):
Class: nitro-imidazole (anti-TB). Use: no standard BU role; mentioned in research for mycobacteria. Risks: QT prolongation. Label source: FDA/EMA docs (TB). Do not use outside trials. CDC

13) Bedaquiline (research contexts only):
Class: diarylquinoline (ATP synthase inhibitor). Use: TB only; not standard for BU. Risks: QT prolongation. Label source: FDA Sirturo label. Avoid unless in trial. CDC

14) Ofloxacin (older fluoroquinolone):
Class: fluoroquinolone. Use: historical/alternative; safety concerns similar to class. Label source: FDA ofloxacin label. Not first-line. CDC

15) Ethambutol (TB drug; NOT recommended for BU):
Class: cell wall-active anti-TB. Note: lacks evidence for BU benefit; included here only to caution against extrapolating TB regimens. Risks: optic neuritis. Label source: FDA ethambutol label. CDC

16) Isoniazid (TB drug; NOT recommended for BU):
Class: mycolic acid inhibitor. Note: not used for BU; toxin-mediated disease responds better to rifampin-macrolide strategy. Risks: hepatitis, neuropathy (give B6 if used for other reasons). Label source: FDA isoniazid label. CDC

17) Streptomycin (legacy regimen partner):
Class: aminoglycoside. Use: formerly used with rifampin; now avoided due to toxicity and availability of all-oral therapy. Risks: ototoxicity/nephrotoxicity. Label source: FDA streptomycin label. PMC

18) Ciprofloxacin (fluoroquinolone alternative; rare):
Class: fluoroquinolone. Use: not preferred; consider risks vs. unclear benefit. Label source: FDA ciprofloxacin label. CDC

19) Minocycline (tetracycline alternative; rare):
Class: tetracycline. Use: occasional substitution with expert input; monitor for vestibular effects and pigmentation. Label source: FDA minocycline label. CDC

20) Topical antibiotics (not a substitute for systemic therapy):
Note: do not replace systemic antibiotics; limited role preventing secondary infection around wound edges if prescribed. Rationale: BU is deep mycobacterial disease; topical agents cannot reach toxin-damaged tissue adequately. Source: wound-care and BU management reviews. Taylor & Francis Online

---

Dietary molecular supplements

1) Vitamin C (ascorbic acid):
Dose: dietary focus; if supplementing, many wound protocols use 200–500 mg/day short-term when intake is poor. Function: collagen cross-linking and antioxidant support. Mechanism: cofactor for prolyl/lysyl hydroxylases; may improve healing in deficiency states. Evidence: systematic reviews show benefit mainly when deficiency or pressure-ulcer risk exists. PMC+1

2) Zinc:
Dose: only if deficient; typical short-term 15–30 mg elemental zinc/day, avoid >40 mg/day long-term to prevent copper deficiency. Function: epithelialization and immune function. Mechanism: DNA synthesis and keratinocyte migration. Evidence: mixed; benefits clearest when deficiency is present. drjeffreyjanis.com

3) Protein (including arginine-rich foods):
Dose: meet 1.25–1.5 g/kg/day protein if malnourished. Function: substrate for collagen and immune mediators. Mechanism: arginine supports nitric-oxide–mediated perfusion; overall protein prevents catabolism. Evidence: nutrition guidelines for wound healing emphasize adequate protein intake. E-ACNM

4) Vitamin A:
Dose: prefer diet (leafy greens, orange vegetables). Supplement only if documented deficiency; avoid high doses in pregnancy. Function: epithelial differentiation and immune defense. Mechanism: retinoids regulate keratinocyte maturation. Evidence: narrative and clinical reviews support a role mainly in deficiency. ScienceDirect

5) Vitamin D:
Dose: follow local guidance to correct deficiency (often 800–2000 IU/day). Function: immunomodulation and antimicrobial peptide induction. Mechanism: VDR-mediated innate immune effects. Evidence: general wound and infection literature suggests benefits when deficient; BU-specific data are lacking. ScienceDirect

6) Omega-3 fatty acids:
Dose: through diet (fish, flax) or 1–2 g/day EPA+DHA if advised. Function: anti-inflammatory support. Mechanism: resolvins modulate inflammation, potentially aiding repair. Evidence: narrative review links omega-3s to improved healing in some settings. ResearchGate

7) B-complex vitamins (esp. B6, folate, B12):
Dose: dietary sufficiency or standard multivitamin if intake is poor. Function: cell division and RBC production. Mechanism: coenzymes for nucleotide synthesis and methylation. Evidence: comprehensive review notes roles across repair phases; supplement if diet is inadequate. ResearchGate

8) Probiotics (oral or topical—adjunct only):
Dose: strain-specific; evidence heterogeneous. Function: may modulate local inflammation and barrier repair. Mechanism: competitive inhibition, immune signaling; topical forms being studied. Evidence: systematic and scoping reviews show promising but inconsistent effects. PMC+2PMC+2

9) Polyphenol-rich foods (berries, tea, cocoa):
Dose: food-based inclusion. Function: antioxidant/anti-inflammatory support. Mechanism: NF-κB modulation and ROS scavenging. Evidence: narrative review suggests potential benefit as part of a balanced diet. ResearchGate

10) Iron (only if deficient):
Dose: treat documented iron deficiency per guidelines. Function: oxygen transport aiding collagen hydroxylation. Mechanism: supports hemoglobin and enzymes in repair. Evidence: general wound-care nutrition guidance; avoid unnecessary iron. E-ACNM

---

Immunity-booster / regenerative / stem cell drugs

There are no approved “stem cell drugs” for Buruli ulcer. Do not use unapproved regenerative products. Below are immune-supportive or regenerative-adjacent strategies sometimes discussed in wound care; they do not replace antibiotics. Taylor & Francis Online

1) Vitamin D (correct deficiency):
Dose: usual 800–2000 IU/day unless otherwise advised. Function: supports innate immunity. Mechanism: induces antimicrobial peptides (cathelicidin). ScienceDirect

2) Protein/arginine supplementation (if malnourished):
Dose: target 1.25–1.5 g/kg/day protein. Function: immune and tissue repair; not a drug but a key therapeutic nutrient. Mechanism: supports NO-mediated perfusion and collagen. E-ACNM

3) Probiotic adjunct (selected strains):
Dose: strain-specific per product. Function: immune modulation and barrier support. Mechanism: cytokine signaling and competitive inhibition on skin/gut. PMC

4) Topical silicone for scars (after closure):
Dose: apply per product for weeks. Function: improves scar quality (a regenerative outcome). Mechanism: hydration and fibroblast modulation. Taylor & Francis Online

5) Physical therapy (functional regeneration):
Dose: scheduled sessions during and after healing. Function: restores range and strength (regenerative function). Mechanism: mechanotransduction promotes organized collagen. World Health Organization

6) PRP/biologics (research-context only):
Dose: specialist procedures; not standard for BU. Function/mechanism: growth factors may stimulate repair, but BU-specific evidence is lacking—avoid outside trials. Taylor & Francis Online

---

Surgeries (what they are and why done)

1) Conservative surgical debridement:
Careful removal of dead tissue that antibiotics cannot clear quickly. Why: speed formation of a clean granulating bed when slough is heavy or undermined edges prevent contraction. Taylor & Francis Online

2) Split-thickness skin graft (STSG):
Transplant a thin skin layer from a donor site onto a well-granulated BU bed after infection control. Why: cover large defects faster, reduce dressing burden, and improve function. Taylor & Francis Online

3) Local flap coverage:
Rotate nearby tissue with its blood supply to cover exposed bone/tendon or cavities. Why: provide durable coverage where grafts may fail. Taylor & Francis Online

4) Contracture release:
Surgically release tight scars across joints once healed. Why: restore movement and independence after large peri-articular ulcers. Taylor & Francis Online

5) Amputation (rare, last resort):
Reserved for life-threatening complications or non-functional limb with chronic infection. Why: prevent systemic risk when all other options fail. Taylor & Francis Online

---

Preventions

1. Avoid mosquito bites in endemic areas: long sleeves, long pants, enclosed shoes. NSW Health+1
2.  Use repellents with DEET, picaridin, or oil of lemon eucalyptus on exposed skin. NSW Health
3. Wear gardening gloves and protective clothing during outdoor work. Health Victoria
4. Clean and cover all cuts and scratches quickly with soap, antiseptic, and a dressing. Health Victoria
5. Reduce backyard mosquito habitats (tip out still water, maintain screens). Healthdirect
6. Avoid wading in stagnant or slow-moving water with unprotected skin. PMC
7. Seek early medical review for persistent nodules, plaques, or ulcers—treatment is easier early. infontd.org
8.  Community education on BU signs and the value of early care. World Health Organization
9. Protect healing wounds from trauma and insect bites to prevent secondary problems. Taylor & Francis Online
10. Note that no vaccine exists; general bite/skin protection remains key. NSW Health

---

When to see a doctor

See a clinician as soon as you notice a painless nodule, plaque, or swelling that enlarges over weeks—especially after travel or residence in an endemic area—or any non-healing ulcer on limbs. Also seek care urgently for fever, spreading redness, severe pain, foul odor, rapidly increasing size, exposed bone/tendon, or limited joint movement. Early treatment with rifampicin + clarithromycin for 8 weeks and proper wound care can prevent surgery and disability. Medscape+1

---

Foods to eat & to avoid

Eat (support repair):

1. Lean proteins (fish, eggs, legumes) for collagen building blocks. E-ACNM

2. Citrus/guava/berries (vitamin C for collagen). PMC

3. Leafy greens & orange vegetables (vitamin A precursors). ScienceDirect

4. Nuts & seeds (zinc, healthy fats). drjeffreyjanis.com

5. Whole grains (B-vitamins and energy). ResearchGate

6. Yogurt/fermented foods (possible probiotic benefit; adjunct only). PMC

7. Oily fish (omega-3s to modulate inflammation). ResearchGate

8. Plenty of water (hydration for perfusion). E-ACNM

9. Iron-rich foods if deficient (lentils, meat) guided by testing. E-ACNM

10. Small, frequent balanced meals to meet higher energy/protein targets. E-ACNM

Avoid or limit:

1. Smoking (impairs perfusion). ScienceDirect

2. Excess alcohol (immune suppression, poor nutrition). ScienceDirect

3. Ultra-processed sugary foods (empty calories, glycemic swings). ResearchGate

4. Very salty foods if edema is a problem. Taylor & Francis Online

5. Unnecessary herbal/botanical topicals on open wounds (irritation risk). Taylor & Francis Online

6. High-dose zinc long-term without testing (copper deficiency risk). drjeffreyjanis.com

7. Grapefruit juice if on clarithromycin (interaction risk). FDA Access Data

8. QT-prolonging combos (certain antihistamines/antiarrhythmics) with macrolides/fluoroquinolones—check with your clinician. FDA Access Data+1

9. NSAID overuse if kidney risk and on aminoglycosides (rare cases). CDC

10. Self-treating with topical antibiotics only—BU needs systemic therapy. Taylor & Francis Online

---

FAQs

1) Is Buruli ulcer contagious between people?
Person-to-person spread is uncommon; infections are linked to environments near slow-moving water and possibly insect exposure in some areas. World Health Organization+1

2) What is the standard treatment?
Eight weeks of rifampicin + clarithromycin plus good wound care; many patients do not need surgery if treated early. World Health Organization

3) Why do ulcers feel painless?
The mycolactone toxin can reduce local pain and suppress inflammation while damaging tissue, so ulcers may be large but oddly painless. PMC

4) How long until the wound closes?
Healing may take months, even after bacteria are killed; physiotherapy and nutrition help recovery. PMC

5) Do I need injections?
Not usually. Older regimens used streptomycin; WHO now prefers all-oral rifampicin + clarithromycin. World Health Organization

6) Can children and pregnant people be treated?
Yes—with tailored regimens and safety checks by specialists (macrolide/ rifampin choices and doses vary). Follow WHO/local guidance. WHO | Regional Office for Africa

7) Will I have a scar?
Large ulcers can scar; early treatment, good wound care, and later scar management (silicone, massage) improve cosmetic and functional results. Taylor & Francis Online

8) What if antibiotics upset my stomach?
Report side effects promptly. Alternatives (e.g., azithromycin) or supportive care can often be used safely. Never stop antibiotics without medical advice. FDA Access Data

9) Can I work during treatment?
Many can, with protected dressings and scheduled care. Offloading and light duties may be needed until healing advances. Taylor & Francis Online

10) Do probiotics help?
Evidence is mixed; they may help some types of wounds but are not a cure for BU and should not replace antibiotics. PMC

11) Are there vaccines?
No specific vaccine exists for BU; prevention relies on bite protection and wound hygiene. NSW Health

12) Do I need surgery?
Only sometimes—e.g., heavy dead tissue, very large cavities, or later contractures. Many heal without surgery if treated early. Taylor & Francis Online

13) What drug interactions matter most?
Rifampin induces liver enzymes and reduces levels of many drugs (e.g., warfarin, oral contraceptives). Clarithromycin can raise levels/QT risk with other medicines. Always share your medication list. FDA Access Data+1

14) How can communities reduce BU?
Education for early care, bite prevention, and prompt cleaning/covering of wounds helps reduce disease burden. World Health Organization

15) Where can clinicians find full guidance?
WHO guidance and reviews summarize diagnosis, antibiotic regimens, and rehabilitation. WHO | Regional Office for Africa+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 06, 2025.

PDF Documents For This Disease Condition References